BofA Securities Adjusts BXP Price Target to $83
BofA Securities analyst Jeffrey Spector has maintained a Buy rating on BXP, Inc. while lowering the firm's price target from $85 to $83.
Stocks · News reference
UBS analyst Michael Goldsmith has maintained a 'Hold' rating on BXP, Inc. while adjusting the price target from $70 to $66.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
BofA Securities analyst Jeffrey Spector has maintained a Buy rating on BXP, Inc. while lowering the firm's price target from $85 to $83.
Boston Properties (BXP) reported strong Q3 2026 results with occupancy reaching 89.4%, exceeding forecasts. The company raised over $520 million in asset sales to reduce debt and is benefiting from limited new office supply in premier markets, which is restoring pricing power and allowing rent increases on expiring leases. Management expects continued occupancy gains and NOI growth driven by lease expirations in coming years.
Healthpeak Properties (DOC) reported Q3 2026 FFOA of $0.44 per share, beating estimates by 2.3%, with revenues up 16.3% YoY to $820.9 million. The company raised 2026 FFOA guidance to $1.76-$1.78 per share, supported by solid outpatient leasing, improving lab occupancy, and strong senior housing performance from Janus Living. However, operating expenses surged 30% YoY, and the company carries a Zacks Rank #4 (Sell) rating.
Jefferies has updated its price target for BXP, Inc., raising it from $66 to $70.